The Clear Leader in Breast Imaging AI
Faced with the complexity of breast cancer screening, artificial intelligence solutions have become a valuable aid for radiologists. For your Breast AI solution, choose the clear leader. Meet with our team in booth AI-20 to discover how iCAD's Breast AI suite can enhance patient care at your facility.
But not all AI is created equal.
iCAD® is the only company that offers a high performing suite of
AI solutions for breast cancer detection, density assessment, and short-term risk evaluation. Together, these technologies deliver comprehensive personalized screening.
These solutions are clinically proven to assist clinicians in their daily clinical practice and address the five key challenges many radiologists face today:
Join us on Wednesday, May 18 from 1:30 PM – 2:30 PM ET Scientific Session 4
Real-World Breast Cancer Detection Before and After the Implementation of an Artificial Intelligence Detection System in a Digital Breast Tomosynthesis Screening Program
Colleen M Madden, MD
Assistant Clinical Professor of Radiology
IUH Ball Memorial Hospital
Indiana University School of Medicine
Muncie, Indiana
Scientific Session 4 | May 18, 2022 Real-World Breast Cancer Detection Before and After the Implementation of an Artificial Intelligence Detection System in a Digital Breast Tomosynthesis Screening Program
Colleen M Madden, MD
Assistant Clinical Professor of Radiology
IUH Ball Memorial Hospital
Indiana University School of Medicine
Muncie, Indiana
Not All AI Is Created Equal
Discover the Unrivaled Power of ProFound AI - We invite you to look beyond the hype and experience ProFound confidence in your AI solutions, without compromise.
“As technology is advancing and becoming a more integral part of our day-to-day workflow, partnering with organizations that provide a clear advantage in AI technologies, like iCAD, has been a critical focus for our facility in recent years. We have done a thorough evaluation of all of the other available AI technologies for breast imaging, but ultimately we found ProFound AI to be the best solution. With its multi-vendor flexibility, ProFound AI seamlessly integrated into our system and clinical workflow.”
Matt Dewey, Chief Information Officer, Wake Radiology
Scientific Session 4 | May 18, 2022 Real-World Breast Cancer Detection Before and After theImplementation of an Artificial Intelligence Detection System in a DigitalBreast Tomosynthesis Screening Program
Wednesday, May 18, 2022 | 1:30 PM – 2:30 PM EDT
Colleen M Madden, MD
Assistant Clinical Professor of Radiology
IUH Ball Memorial Hospital
Indiana University School of Medicine
Muncie, Indiana
Real-World Breast Cancer Detection Before and After theImplementation of an Artificial Intelligence Detection System in a DigitalBreast Tomosynthesis Screening Program Wednesday, May 18, 2022 | 1:30 PM – 2:30 PM EDT Colleen M Madden, MD
Assistant Clinical Professor of Radiology
IUH Ball Memorial Hospital
Indiana University School of Medicine
Muncie, Indiana
Unrivaled by any other AI solution available today, ProFound AI improves radiologists’ sensitivity by 8 percent, and reduces false positives and unnecessary patient recall rates by 7.2 percent. The latest version offers up to a 10% incremental improvement in specificity performance while maintaining an industry-leading high sensitivity level.
ProFound AI delivers unmatched, clinically proven time-savings benefits to radiologists, slashing reading time by 52.7%. Further, Certainty of Finding and Case Scores assist in prioritizing caseload and clinical decision-making, reducing physician burnout.
With thousands of installations worldwide, ProFound AI offers multi-vendor compatibility and seamlessly integrates into the diagnostic process.
Now compatible with Hologic Clarity HD®!
Today’s unprecedented screening challenges call for unparalleled AI solutions, streamlining workflow and elevating outcomes. ProFound AI flexibly integrates with major PACS, offering an intuitive, system-wide solution for improved workflow and decision support in any reading environment.
With market-leading agility, ProFound AI offers a practical enterprise-wide solution with powerful results. With access to our complete portfolio of cancer detection, density assessment and risk evaluation solutions on one centralized server, streamlined deployment of state-of-the-art breast imaging technology at scale is simple.
Now available for 2D and 3D mammography, ProFound AI® Risk is the world’s first clinical decision support tool that provides an accurate short-term, breast cancer risk estimation that is truly personalized for each woman. Specifically designed to factor in racial and ethnic backgrounds, ProFound AI Risk offers an inclusive, first-in-kind approach to precision screening.
"Et harum quidem rerum facilis est et expedita distinctio!"
"Nam libero tempore, cum soluta nobis est eligendi."
"Temporibus autem quibusdam et aut officiis debitis!"
1. Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
2. For GE and Hologic only. Uses 2D synthesized images.
3. iCAD data on file.
